Back

Real-world outcomes of mavacamten in obstructive hypertrophic cardiomyopathy (HCP) in the United States: a pooled analysis

11 May 2026 (11:30 - 12:30)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (4) Hypertrophic Cardiomyopathy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Ervant Maksabedian Hernandez

Princeton (United States of America)

7 More presentations in this session

Presentation thumbnail
Differences in clinical, morphological and laboratory parameters between hypertrophic cardiomyopathy patients with and without heart failure
Doctor S. Wisniowska-Smialek (Krakow, PL)
Abstract Slides
Presentation thumbnail
Clinical and imaging predictors of mortality and adverse outcomes in a latin american cohort with hypertrophic cardiomyopathy
Doctor M. Bustamante (Medellin, CO)
Abstract Slides
Presentation thumbnail
Are variants of uncertain significance clinically equivalent to genotype-negative status in hypertrophic cardiomyopathy? A single-center analysis
Doctor H. Santos Moreira (Porto, PT)
Abstract Slides
Presentation thumbnail
Beyond the genotype: prevalence, phenotypic expression and prognosis in hypertrophic cardiomyopathy
Doctor H. Santos Moreira (Porto, PT)
Abstract Slides
Presentation thumbnail
Apical hypertrophic cardiomyopathy in a real-world cohort: phenotypic features, sudden cardiac death risk assessment and clinical outcomes
Doctor H. Santos Moreira (Porto, PT)
Abstract Slides

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (4)

The Event

Event poster

Heart Failure 2026

11 May 2026 11:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources